Search

Search Constraints

You searched for: Author/Creator Brillanti, S.

Search Results

2. Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice. (10th February 2016)

3. Immune inflammation indicators and ALBI score to predict occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. Issue 1 (February 2018)

4. Indocyanine green retention test predict the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients. (February 2019)

5. Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients. Issue 1 (16th February 2017)

6. P.04.2 THE RISK OF HEPATIC DECOMPENSATION IS REDUCED, BUT NOT ABOLISHED AFTER DIRECT-ACTING ANTIVIRALS: THE ROLE OF SPLEEN STIFFNESS MEASUREMENT. (25th March 2019)

7. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment. (10th February 2016)

9. Safety and efficacy of direct‐acting antivirals for the treatment of chronic hepatitis C in a real‐world population aged 65 years and older. Issue 6 (2nd February 2017)